

BMPR-IB (H-44): sc-25455

BACKGROUND

Members of the transforming growth factor β superfamily bind to a pair of transmembrane proteins, known as receptor types I and II, which contain serine/threonine kinases and associate to form a signaling complex. Two type I receptors have been characterized, BMPR-IA (also designated SKR5, ALK-3, and BRK-1) and BMPR-IB (also designated ALK-6 and SKR 6), that bind to bone morphogenetic proteins (BMP)-2, BMP-4, and osteogenic protein (OP)-1 (also designated BMP-7). BMPR-IA and BMPR-IB are both expressed in human glioma cell lines. The type II receptor, BMPR-II, efficiently binds to OP-1 and BMP-2 and weakly binds BMP-4, and it is widely expressed in different tissues, including brain. The BMP receptor family members are thought to mediate distinct effects on gene expression, cell differentiation, and morphogenesis in a dose dependent fashion.

CHROMOSOMAL LOCATION

Genetic locus: BMPR1B (human) mapping to 4q22.3; Bmpr1b (mouse) mapping to 3 H1.

SOURCE

BMPR-IB (H-44) is a rabbit polyclonal antibody raised against amino acids 15-58 of BMPR-IB of human origin.

PRODUCT

Each vial contains 200 μ g IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

BMPR-IB (H-44) is recommended for detection of BMPR-IB of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000). BMPR-IB (H-44) is also recommended for detection of BMPR-IB in additional species, including equine, canine, bovine and porcine.

Suitable for use as control antibody for BMPR-IB siRNA (h): sc-40218, BMPR-IB siRNA (m): sc-40219, BMPR-IB shRNA Plasmid (h): sc-40218-SH, BMPR-IB shRNA Plasmid (m): sc-40219-SH, BMPR-IB shRNA (h) Lentiviral Particles: sc-40218-V and BMPR-IB shRNA (m) Lentiviral Particles: sc-40219-V.

Molecular Weight of BMPR-IB: 45 kDa.

Positive Controls: DU 145 cell lysate: sc-2268, LNCaP cell lysate: sc-2231 or PC-3 cell lysate: sc-2220.


STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.


RESEARCH USE

For research use only, not for use in diagnostic procedures.

DATA



BMPR-IB (H-44): sc-25455. Western blot analysis of BMPR-IB expression in DU 145 (A), LNCaP (B) and PC-3 (C) whole cell lysates.



BMPR-IB (H-44): sc-25455. Immunoperoxidase staining of formalin fixed, paraffin-embedded human liver tissue showing cytoplasmic staining of hepatocytes at low (A) and high (B) magnification. Kindly provided by The Swedish Human Protein Atlas (HPA) program.

SELECT PRODUCT CITATIONS

1. Tomoeda, M., et al. 2008. PLAP-1/aspurin inhibits activation of BMP receptor via its leucine-rich repeat motif. *Biochem. Biophys. Res. Commun.* 371: 191-196.
2. Chen, D.F., et al. 2009. Autocrine BMP4 signaling involves effect of cholesterol myristate on proliferation of mesenchymal stem cells. *Steroids* 74: 1066-1072.
3. Medici, D., et al. 2010. Conversion of vascular endothelial cells into multipotent stem-like cells. *Nat. Med.* 16: 1400-1406.
4. Haubold, M., et al. 2010. Bone morphogenetic protein 4 (BMP4) signaling in retinoblastoma cells. *Int. J. Biol. Sci.* 6: 700-715.
5. Sun, R.Z., et al. 2010. Expression of GDF-9, BMP-15 and their receptors in mammalian ovary follicles. *J. Mol. Histol.* 41: 325-332.
6. Sakai, H., et al. 2012. Augmented autocrine bone morphogenetic protein (BMP) 7 signaling increases the metastatic potential of mouse breast cancer cells. *Clin. Exp. Metastasis* 29: 327-338.
7. Lee, H.K., et al. 2012. Odontogenic ameloblasts-associated protein (ODAM), via phosphorylation by bone morphogenetic protein receptor type IB (BMPR-IB), is implicated in ameloblast differentiation. *J. Cell. Biochem.* 113: 1754-1765.
8. Giovanini, A.F., et al. 2012. Leukocyte-platelet-rich plasma (L-PRP) induces an abnormal histophenotype in craniofacial bone repair associated with changes in the immunopositivity of the hematopoietic clusters of differentiation, osteoproteins, and TGF- β 1. *Clin. Implant Dent. Relat. Res.* E-published.



Try **BMPR-IB (2E2): sc-293428**, our highly recommended monoclonal alternative to BMPR-IB (H-44).